AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access

 
• By Emily Hayes

In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.

Female uterus and ovaries abstract background.

More from New Products

More from Scrip